Lenvima contains the active ingredient lenvatinib, an oral targeted therapy classified as a multi-kinase inhibitor. It is approved for the treatment of several cancers, including differentiated thyroid cancer, advanced renal cell carcinoma (RCC), unresectable hepatocellular carcinoma (HCC), and certain cases of advanced endometrial carcinoma, either alone or in combination with other anticancer therapies.

Lenvatinib works by inhibiting multiple receptor tyrosine kinases involved in tumor growth, angiogenesis (the formation of new blood vessels), and cancer progression. Its targets include vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT. By blocking these pathways, Lenvima helps reduce tumor blood supply and inhibit cancer cell growth.

The medication is administered orally as capsules and is typically taken once daily. Dosage varies depending on the cancer type, body weight, and whether it is used alone or in combination with other therapies. Patients should take Lenvima exactly as prescribed and undergo regular monitoring during treatment.

Clinical studies have shown that Lenvima can improve progression-free survival and disease control in several cancer types. It has become an important treatment option in oncology, particularly for patients with advanced or difficult-to-treat cancers.

Common side effects may include hypertension, fatigue, diarrhea, decreased appetite, weight loss, nausea, proteinuria, and hand-foot syndrome. Serious adverse reactions can include severe hypertension, bleeding, heart problems, liver toxicity, kidney impairment, and gastrointestinal perforation. Regular monitoring of blood pressure and organ function is recommended throughout treatment.